Factor VIII products and inhibitor development in severe hemophilia A

Samantha C. Gouw; Johanna G. Van Der Bom; Rolf Ljung; Carmen Escuriola; Ana R. Cid; Ségolène Claeyssens-Donadel; Christel Van Geet; Gili Kenet; Anne Mäkipernaa; Angelo Claudio Molinari; Wolfgang Muntean; Rainer Kobelt; George Rivard; Elena Santagostino; Angela Thomas; H. Marijke Van Den Berg

doi:10.1056/NEJMoa1208024

Factor VIII products and inhibitor development in severe hemophilia A

Samantha C. Gouw, Johanna G. Van Der Bom, Rolf Ljung, Carmen Escuriola, Ana R. Cid, Ségolène Claeyssens-Donadel, Christel Van Geet, Gili Kenet, Anne Mäkipernaa, Angelo Claudio Molinari, Wolfgang Muntean, Rainer Kobelt, George Rivard, Elena Santagostino, Angela Thomas, H. Marijke Van Den Berg

Research output: Contribution to journal › Article

Abstract

BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,

Original language	English
Pages (from-to)	231-239
Number of pages	9
Journal	New England Journal of Medicine
Volume	368
Issue number	3
DOIs	https://doi.org/10.1056/NEJMoa1208024
Publication status	Published - Jan 17 2013

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMoa1208024

Fingerprint Dive into the research topics of 'Factor VIII products and inhibitor development in severe hemophilia A'. Together they form a unique fingerprint.

Cite this

Gouw, S. C., Van Der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens-Donadel, S., Van Geet, C., Kenet, G., Mäkipernaa, A., Molinari, A. C., Muntean, W., Kobelt, R., Rivard, G., Santagostino, E., Thomas, A., & Van Den Berg, H. M. (2013). Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine, 368(3), 231-239. https://doi.org/10.1056/NEJMoa1208024

Factor VIII products and inhibitor development in severe hemophilia A. / Gouw, Samantha C.; Van Der Bom, Johanna G.; Ljung, Rolf; Escuriola, Carmen; Cid, Ana R.; Claeyssens-Donadel, Ségolène; Van Geet, Christel; Kenet, Gili; Mäkipernaa, Anne; Molinari, Angelo Claudio; Muntean, Wolfgang; Kobelt, Rainer; Rivard, George; Santagostino, Elena; Thomas, Angela; Van Den Berg, H. Marijke.

In: New England Journal of Medicine, Vol. 368, No. 3, 17.01.2013, p. 231-239.

Research output: Contribution to journal › Article

Gouw, SC, Van Der Bom, JG, Ljung, R, Escuriola, C, Cid, AR, Claeyssens-Donadel, S, Van Geet, C, Kenet, G, Mäkipernaa, A, Molinari, AC, Muntean, W, Kobelt, R, Rivard, G, Santagostino, E, Thomas, A & Van Den Berg, HM 2013, 'Factor VIII products and inhibitor development in severe hemophilia A', New England Journal of Medicine, vol. 368, no. 3, pp. 231-239. https://doi.org/10.1056/NEJMoa1208024

Gouw, Samantha C. ; Van Der Bom, Johanna G. ; Ljung, Rolf ; Escuriola, Carmen ; Cid, Ana R. ; Claeyssens-Donadel, Ségolène ; Van Geet, Christel ; Kenet, Gili ; Mäkipernaa, Anne ; Molinari, Angelo Claudio ; Muntean, Wolfgang ; Kobelt, Rainer ; Rivard, George ; Santagostino, Elena ; Thomas, Angela ; Van Den Berg, H. Marijke. / Factor VIII products and inhibitor development in severe hemophilia A. In: New England Journal of Medicine. 2013 ; Vol. 368, No. 3. pp. 231-239.

@article{db376039e7704174bad1031d2514f287,

title = "Factor VIII products and inhibitor development in severe hemophilia A",

abstract = "BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity, ",

author = "Gouw, {Samantha C.} and {Van Der Bom}, {Johanna G.} and Rolf Ljung and Carmen Escuriola and Cid, {Ana R.} and S{\'e}gol{\`e}ne Claeyssens-Donadel and {Van Geet}, Christel and Gili Kenet and Anne M{\"a}kipernaa and Molinari, {Angelo Claudio} and Wolfgang Muntean and Rainer Kobelt and George Rivard and Elena Santagostino and Angela Thomas and {Van Den Berg}, {H. Marijke}",

year = "2013",

month = jan,

day = "17",

doi = "10.1056/NEJMoa1208024",

language = "English",

volume = "368",

pages = "231--239",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "3",

}

TY - JOUR

T1 - Factor VIII products and inhibitor development in severe hemophilia A

AU - Gouw, Samantha C.

AU - Van Der Bom, Johanna G.

AU - Ljung, Rolf

AU - Escuriola, Carmen

AU - Cid, Ana R.

AU - Claeyssens-Donadel, Ségolène

AU - Van Geet, Christel

AU - Kenet, Gili

AU - Mäkipernaa, Anne

AU - Molinari, Angelo Claudio

AU - Muntean, Wolfgang

AU - Kobelt, Rainer

AU - Rivard, George

AU - Santagostino, Elena

AU - Thomas, Angela

AU - Van Den Berg, H. Marijke

PY - 2013/1/17

Y1 - 2013/1/17

N2 - BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,

AB - BACKGROUND: For previously untreated children with severe hemophilia A, it is unclear whether the type of factor VIII product administered and switching among products are associated with the development of clinically relevant inhibitory antibodies (inhibitor development). METHODS: We evaluated 574 consecutive patients with severe hemophilia A (factor VIII activity,

UR - http://www.scopus.com/inward/record.url?scp=84872450786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872450786&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1208024

DO - 10.1056/NEJMoa1208024

M3 - Article

C2 - 23323899

AN - SCOPUS:84872450786

VL - 368

SP - 231

EP - 239

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 3

ER -